Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
Bioorg Med Chem Lett
; 15(23): 5266-9, 2005 Dec 01.
Article
em En
| MEDLINE
| ID: mdl-16185866
ABSTRACT
Replacement of the pentyl chain on our original bicyclo[2.2.2]octyltriazole leads 1 and 2 has led to the discovery that heteroaryl substituted bicyclo[2.2.2]octyltriazoles are potent and selective 11beta-hydroxysteroid dehydrogenase type I (11beta-HSD1) inhibitors with excellent pharmacokinetic profiles.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Triazóis
/
Síndrome Metabólica
/
11-beta-Hidroxiesteroide Desidrogenase Tipo 1
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Bioorg Med Chem Lett
Assunto da revista:
BIOQUIMICA
/
QUIMICA
Ano de publicação:
2005
Tipo de documento:
Article
País de afiliação:
Estados Unidos